Aceragen Inc traded at $0.38 this Monday August 21st, decreasing $0.06 or 13.83 percent since the previous trading session. Looking back, over the last four weeks, Aceragen lost 48.99 percent. Over the last 12 months, its price fell by 95.16 percent. Looking ahead, we forecast Aceragen Inc to be priced at 0.37 by the end of this quarter and at 0.34 in one year, according to Trading Economics global macro models projections and analysts expectations.
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.